Moleculin Biotech announced that an independent Cleveland Clinic review found no clinically significant cardiotoxicity in relapsed/refractory acute myeloid leukemia (R/R AML) patients treated with Annamycin, even at doses exceeding traditional anthracycline limits. The pooled analysis of 90 patients from five trials showed stable heart function, addressing a major barrier to anthracycline use in heavily pretreated AML cases. This favorable cardiac safety profile supports Annamycin's potential as a safer treatment option for R/R AML, with ongoing Phase 3 trials aiming for regulatory approval. The findings may also expand Annamycin's use in other cancers limited by cardiotoxicity concerns.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Alpaca, a brokerage infrastructure startup, secured $435 million in funding to enter prime brokerage services, challenging traditional Wall Street firms. The company’s API supports 94% of US equities and powers tokenized stocks for Kraken. Alpaca’s t...
Raymond James Financial's rating was raised to "Buy" after positive investor event disclosures and a promising preview of its upcoming quarterly results. The company is expected to exceed earnings per share consensus for Q3 FY26, driven by strong per...
Bitcoin and Ethereum experienced combined outflows exceeding $59 million as traders moved funds into stablecoins like USDT and fiat currencies, signaling a cautious stance in the crypto market. This rotation reflects a short-term defensive strategy, ...
Whales have accumulated 70 million XRP over the past week, showing strong confidence despite XRP's price consolidating below resistance levels. The XRP Ledger surpassed 8 million activated accounts, indicating growing network adoption across payments...
